Nitrous Oxide, a Rapid Antidepressant, Has Ketamine-like Effects on Excitatory Transmission in the Adult Hippocampus

Overview

Journal Biol Psychiatry

Publisher Elsevier

Specialty Psychiatry

Date 2022 Sep 1

PMID 36050137

Authors

Yukitoshi Izumi

Fong-Fu Hsu

Charles R Conway

Peter Nagele

Steven J Mennerick

Charles F Zorumski

Affiliations

Soon will be listed here.

Abstract

Background: Nitrous oxide (NO) is a noncompetitive inhibitor of NMDA receptors that appears to have ketamine-like rapid antidepressant effects in patients with treatment-resistant major depression. In preclinical studies, ketamine enhances glutamate-mediated synaptic transmission in the hippocampus and prefrontal cortex. In this study, we examined the effects of NO on glutamate transmission in the hippocampus and compared its effects to those of ketamine.

Methods: Glutamate-mediated synaptic transmission was studied in the CA1 region of hippocampal slices from adult albino rats using standard extracellular recording methods. Effects of NO and ketamine at subanesthetic concentrations were evaluated by acute administration.

Results: Akin to 1 μM ketamine, 30% NO administered for 15-20 minutes resulted in persistent enhancement of synaptic responses mediated by both AMPA receptors and NMDA receptors. Synaptic enhancement by both NO and ketamine was blocked by co-administration of a competitive NMDA receptor antagonist at saturating concentration, but only ketamine was blocked by an AMPA receptor antagonist. Synaptic enhancement by both agents involved TrkB (tropomyosin receptor kinase B), mTOR (mechanistic target of rapamycin), and NOS (nitric oxide synthase) with some differences between NO and ketamine. NO potentiation occluded enhancement by ketamine, and in vivo NO exposure occluded further potentiation by both NO and ketamine.

Conclusions: These results indicate that NO has ketamine-like effects on hippocampal synaptic function at a subanesthetic, but therapeutically relevant concentration. These 2 rapid antidepressants have similar, but not identical mechanisms that result in persisting synaptic enhancement, possibly contributing to psychotropic actions.

Citing Articles

Nitrous oxide exerts rewarding effect via regulating D1 receptor and BDNF pathway in ventral tegmental area-nucleus accumbens dopamine circuit.

Li W, Liu S, Yang S, Lin X, Zhang Z Transl Psychiatry. 2025; 15(1):34.

PMID: 39875366 PMC: 11775255. DOI: 10.1038/s41398-025-03257-y.

Examining memory reconsolidation as a mechanism of nitrous oxide's antidepressant action.

Williams E, Taujanskaite U, Kamboj S, Murphy S, Harmer C Neuropsychopharmacology. 2025; 50(4):609-617.

PMID: 39825109 PMC: 11845508. DOI: 10.1038/s41386-024-02049-0.

Xenon anaesthesia is associated with a reduction in frontal electroencephalogram peak alpha frequency.

McGuigan S, Pelentritou A, Scott D, Sleigh J BJA Open. 2024; 12:100358.

PMID: 39687274 PMC: 11647626. DOI: 10.1016/j.bjao.2024.100358.

Nitrous Oxide activates layer 5 prefrontal neurons via SK2 channel inhibition for antidepressant effect.

Cichon J, Joseph T, Lu X, Wasilczuk A, Kelz M, Mennerick S Res Sq. 2024; .

PMID: 39606485 PMC: 11601843. DOI: 10.21203/rs.3.rs-5141491/v1.

Sertraline modulates hippocampal plasticity via sigma 1 receptors, cellular stress and neurosteroids.

Izumi Y, Reiersen A, Lenze E, Mennerick S, Zorumski C Transl Psychiatry. 2024; 14(1):474.

PMID: 39572523 PMC: 11582653. DOI: 10.1038/s41398-024-03185-3.

References

Maeng S, Zarate Jr C, Du J, Schloesser R, McCammon J, Chen G . Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2007; 63(4):349-52. DOI: 10.1016/j.biopsych.2007.05.028. View

Schreiber K, Ortiz D, Academia E, Anies A, Liao C, Kennedy B . Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins. Aging Cell. 2015; 14(2):265-73. PMC: 4364838. DOI: 10.1111/acel.12313. View

Nosyreva E, Szabla K, Autry A, Ryazanov A, Monteggia L, Kavalali E . Acute suppression of spontaneous neurotransmission drives synaptic potentiation. J Neurosci. 2013; 33(16):6990-7002. PMC: 3661220. DOI: 10.1523/JNEUROSCI.4998-12.2013. View

Ali F, Gerhard D, Sweasy K, Pothula S, Pittenger C, Duman R . Ketamine disinhibits dendrites and enhances calcium signals in prefrontal dendritic spines. Nat Commun. 2020; 11(1):72. PMC: 6946708. DOI: 10.1038/s41467-019-13809-8. View

Caton P, Tousman S, Quock R . Involvement of nitric oxide in nitrous oxide anxiolysis in the elevated plus-maze. Pharmacol Biochem Behav. 1994; 48(3):689-92. DOI: 10.1016/0091-3057(94)90333-6. View

Mennerick S, Jevtovic-Todorovic V, Todorovic S, Shen W, Olney J, Zorumski C . Effect of nitrous oxide on excitatory and inhibitory synaptic transmission in hippocampal cultures. J Neurosci. 1998; 18(23):9716-26. PMC: 6793274. View

Zanos P, Moaddel R, Morris P, Georgiou P, Fischell J, Elmer G . NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016; 533(7604):481-6. PMC: 4922311. DOI: 10.1038/nature17998. View

Zorumski C, Izumi Y . NMDA receptors and metaplasticity: mechanisms and possible roles in neuropsychiatric disorders. Neurosci Biobehav Rev. 2012; 36(3):989-1000. PMC: 3288588. DOI: 10.1016/j.neubiorev.2011.12.011. View

Nagashima K, Zorumski C, Izumi Y . Nitrous oxide (laughing gas) facilitates excitability in rat hippocampal slices through gamma-aminobutyric acid A receptor-mediated disinhibition. Anesthesiology. 2004; 102(1):230-4. DOI: 10.1097/00000542-200501000-00034. View

10.

Abdallah C, Averill L, Gueorguieva R, Goktas S, Purohit P, Ranganathan M . Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. Neuropsychopharmacology. 2020; 45(6):990-997. PMC: 7162891. DOI: 10.1038/s41386-020-0644-9. View

11.

Homayoun H, Moghaddam B . NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007; 27(43):11496-500. PMC: 2954603. DOI: 10.1523/JNEUROSCI.2213-07.2007. View

12.

Nagele P, Palanca B, Gott B, Brown F, Barnes L, Nguyen T . A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression. Sci Transl Med. 2021; 13(597). DOI: 10.1126/scitranslmed.abe1376. View

13.

Widman A, McMahon L . Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy. Proc Natl Acad Sci U S A. 2018; 115(13):E3007-E3016. PMC: 5879689. DOI: 10.1073/pnas.1718883115. View

14.

Tokuda K, ODell K, Izumi Y, Zorumski C . Midazolam inhibits hippocampal long-term potentiation and learning through dual central and peripheral benzodiazepine receptor activation and neurosteroidogenesis. J Neurosci. 2010; 30(50):16788-95. PMC: 3073626. DOI: 10.1523/JNEUROSCI.4101-10.2010. View

15.

Zarate Jr C, Singh J, Carlson P, Brutsche N, Ameli R, Luckenbaugh D . A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006; 63(8):856-64. DOI: 10.1001/archpsyc.63.8.856. View

16.

Castren E, Monteggia L . Brain-Derived Neurotrophic Factor Signaling in Depression and Antidepressant Action. Biol Psychiatry. 2021; 90(2):128-136. DOI: 10.1016/j.biopsych.2021.05.008. View

17.

Krystal J, Abdallah C, Sanacora G, Charney D, Duman R . Ketamine: A Paradigm Shift for Depression Research and Treatment. Neuron. 2019; 101(5):774-778. PMC: 6560624. DOI: 10.1016/j.neuron.2019.02.005. View

18.

Theilmann W, Rosenholm M, Hampel P, Loscher W, Rantamaki T . Lack of antidepressant effects of burst-suppressing isoflurane anesthesia in adult male Wistar outbred rats subjected to chronic mild stress. PLoS One. 2020; 15(6):e0235046. PMC: 7313995. DOI: 10.1371/journal.pone.0235046. View

19.

Jevtovic-Todorovic V, Todorovic S, Mennerick S, Powell S, Dikranian K, Benshoff N . Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant and neurotoxin. Nat Med. 1998; 4(4):460-3. DOI: 10.1038/nm0498-460. View

20.

Gerhard D, Pothula S, Liu R, Wu M, Li X, Girgenti M . GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions. J Clin Invest. 2019; 130(3):1336-1349. PMC: 7269589. DOI: 10.1172/JCI130808. View